Abstract 4503: Pharmacokinetics and pharmacodynamic analysis of eribulin mesylate and paclitaxel in mouse
Authors: Krystyna Wozniak, Ying Wu, Bruce A. Littlefield, Kenichi Nomoto, Christopher DesJardins, Yanke Yu, George Lai, Larisa Reyderman, Barbara S. Slusher
Journal: Cancer Research (2015)

Abstract Neuropathy arising from chemotherapy (CIPN) is a major clinical problem representing the dose-limiting side effect of many antineoplastic drugs. At their respective MTDs, we previously reported paclitaxel and ixabepilone produced more severe deficits in nerve conduction velocity, amplitude and degenerative changes in dorsal root ganglia (DRG) and sciatic nerve (SN) versus eribulin mesylate (Wozniak et al 2011). Similar trends for eribulin to cause less neuropathy have also been reported in the clinic (Cigler and Vadhat 2010, Jain and Cigler 2012, Vadhat et al 2013). The underlying reason for this differential effect remains elusive. Differences in tubulin binding may, in part, explain the differential effect (Perez et al 2009, Jordan et al 2005). Another potential explanation could reside in different pharmacokinetic (PK) and nervous tissue distribution of these agents. Toward this latter point, we conducted tissue distribution and pharmacokinetic studies following acute dosing of eribulin mesylate, paclitaxel and ixabepilone. We reported that while all three drugs rapidly cleared from plasma, they distributed into and cleared slowly (&amp;gt;3 days) from peripheral nervous system tissues (Wozniak et al 2014). We have now extended these studies to look out to 42 days following both acute and 2 week MTD-dosing paradigms evaluating drug pharmacokinetics in plasma, DRG and SN as well as pharmacodynamic measurements of nerve conduction and amplitude. We found plasma levels of eribulin mesylate and paclitaxel rapidly declined over 24h after infusion. In contrast, the levels of eribulin mesylate and paclitaxel persisted at above quantification levels (ranging from 5-10 ng/g) for 7 to 14 days post cessation of 2 week MTD dosing. Eribulin mesylate consistently showed greater distribution into DRG and SN over paclitaxel. When comparing the induced nerve conduction deficits, we found paclitaxel and eribulin mesylate caused reduction of nerve conduction parameters similar to our previous studies, most notably in caudal nerve amplitude (by 80.5% and 54.9% respectively). However these deficits, which were sustained for up to several weeks after cessation of dosing, were more severe with paclitaxel. The findings demonstrate that despite eribulin mesylate showing higher nervous tissue distribution than paclitaxel, eribulin mesylate caused less neurotoxicity as evidenced by milder reductions in nerve conduction and amplitude. This work was financially supported by Eisai. Citation Format: Krystyna Wozniak, Ying Wu, Bruce A. Littlefield, Kenichi Nomoto, Christopher DesJardins, Yanke Yu, George Lai, Larisa Reyderman, Barbara S. Slusher. Pharmacokinetics and pharmacodynamic analysis of eribulin mesylate and paclitaxel in mouse. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4503. doi:10.1158/1538-7445.AM2015-4503